Antigen-Specific mRNA-LNP Therapy with mTOR Inhibition Promotes Treg Cells and Limits Allergy

The authors investigate whether combining an allergen-encoded mRNA-lipid nanoparticle (mRNA-LNP) vaccine with an mTOR inhibitor can enhance regulatory T-cell responses and improve immune tolerance in allergic diseases. Their findings indicate that this combination effectively promotes the generation of regulatory T cells, reduces Th2 responses, and limits allergic symptoms in a preclinical model of asthma. This approach suggests a promising strategy for enhancing regulatory immunity in allergy treatment.